The projected growth of the nanomedicine market mirrors the increase in commercial interest and investment in the field. Yet, amidst this optimism, research efforts have often been geared towards developing innovative materials, and less on bringing these innovations to market. In this article, we present a strategic approach of ‘commercialization by design’ to overcome various challenges related to commercialization. This approach shifts the focus from materials-centric development to one driven by market demands, evaluating nanomedicines considering factors like reimbursement restrictions and unmet medical needs, and aiming to generate robust evidence for regulatory authorities, Health Technology Assessment bodies and Payers alike. We highlight the linkages from the market backwards to the preclinical phase, where nanomedicines are tailored to specific clinician-identified requirements. Transitioning from a technology ‘push’ model to one with market ‘pull’ will enhance the commercial success of nanomedicines.

中文翻译：

---

纳米药物商业化的战略方面


纳米医学市场的预计增长反映了该领域商业兴趣和投资的增加。然而，在这种乐观情绪中，研究工作往往侧重于开发创新材料，而不是将这些创新推向市场。在本文中，我们提出了一种“设计商业化”的战略方法，以克服与商业化相关的各种挑战。这种方法将重点从以材料为中心的开发转移到以市场需求为驱动的开发，考虑报销限制和未满足的医疗需求等因素来评估纳米药物，并旨在为监管机构、卫生技术评估机构和付款人提供强有力的证据。我们强调从市场向后到临床前阶段的联系，其中纳米药物是根据临床医生确定的特定要求量身定制的。从技术“推动”模式转变为市场“拉动”模式将提高纳米药物的商业成功。